tirofiban has been researched along with arachidonic acid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faul, JD; Huang, J; Lucchesi, BR; Rebello, SS | 1 |
| Fisher, I; Ritter, JM; Robinson, P | 1 |
| Rodrigues, HL | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
1 review(s) available for tirofiban and arachidonic acid
| Article | Year |
|---|---|
[Update on the treatment with platelet antiaggregation agents].
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Arachidonic Acid; Cell Membrane; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Thromboxane A2; Tirofiban; Tyrosine | 2001 |
1 trial(s) available for tirofiban and arachidonic acid
| Article | Year |
|---|---|
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
2 other study(ies) available for tirofiban and arachidonic acid
| Article | Year |
|---|---|
Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Topics: Adenosine Diphosphate; Animals; Antibodies, Monoclonal; Arachidonic Acid; Bleeding Time; Blood Flow Velocity; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Citrates; Dogs; Dose-Response Relationship, Drug; Female; Heparin; Immunoglobulin Fab Fragments; Male; Mesylates; Mice; Peptides, Cyclic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
Topics: Abciximab; Antibodies, Blocking; Antibodies, Monoclonal; Arachidonic Acid; Female; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |